pegcetacoplan geographic atrophy
Selected indexed studies
- Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials. (Lancet, 2023) [PMID:37865470]
- WITHDRAWN: Pegcetacoplan in the treatment of geographic atrophy. (Immunotherapy, 2023) [PMID:37259853]
- Treatment of geographic atrophy: an update on data related to pegcetacoplan. (Curr Opin Ophthalmol, 2024) [PMID:37815317]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials. (2023) pubmed
- Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial. (2020) pubmed
- Pegcetacoplan Treatment for Geographic Atrophy in Age-Related Macular Degeneration Over 36 Months: Data From OAKS, DERBY, and GALE. (2025) pubmed
- Pegcetacoplan for Geographic Atrophy Over 30 Months: Data From OAKS, DERBY, and the GALE Long-Term Extension Study. (2025) pubmed
- Disease Activity and Therapeutic Response to Pegcetacoplan for Geographic Atrophy Identified by Deep Learning-Based Analysis of OCT. (2025) pubmed
- WITHDRAWN: Pegcetacoplan in the treatment of geographic atrophy. (2023) pubmed
- Treatment of geographic atrophy: an update on data related to pegcetacoplan. (2024) pubmed
- Pegcetacoplan Treatment and Consensus Features of Geographic Atrophy Over 24 Months. (2024) pubmed
- Advancements in the treatment of geographic atrophy: focus on pegcetacoplan in age-related macular degeneration. (2023) pubmed
- Geographic Atrophy Progression in Clinical Practice Before and After Pegcetacoplan Treatment. (2025) pubmed